02816nas a2200289   4500008004100000022001400041245017700055210006900232260000800301300001100309490000800320520181800328653002102146653001502167653002302182653001502205653001602220653001302236100002502249700001802274700002202292700002202314700001902336700002802355700002202383856012102405       2020                        eng d  a0928-493100aLHRH-conjugated, PEGylated, poly-lactide-co-glycolide nanocapsules for targeted delivery of combinational chemotherapeutic drugs Docetaxel and Quercetin for prostate cancer0 aLHRHconjugated PEGylated polylactidecoglycolide nanocapsules for  cSEP  a1110350 v1143 a<p>One of the major challenges in effective cancer chemotherapy is the severe systemic cytotoxicities of anticancer drugs on healthy tissues. The present study reports chemically modified polymeric nanocapsules (NCs) encapsulating combination of chemotherapeutic drugs Docetaxel (DTX) and Quercetin (QU) for its active targeting to prostate cancer (PCa). The active targeting was achieved by conjugating Luteinizing-hormone-releasing hormone (LHRH) ligand to poly-lactide-co-glycolide (PLGA) using polyethylene glycol (PEG) as a spacer. The structure of the conjugates was characterized and confirmed using H-1 NMR and ATR-FTIR. The drug encapsulated NCs showed a homogenous size distribution with their size ranging between 120 and 150 nm, and exhibited a negative zeta potential in the range of - 20 to - 40 mV. The in vitro release studies highlighted the sustained drug release pattern from the respective NCs; while the PEG coating to polymeric NCs provided serum stability to the NCs. The in vitro biological evaluation of the NCs was conducted using PC-3 and LNCaP cell lines. The results of the cellular uptake studies showed a significantly higher untake of the LHRH targeted NCs, while the LHRH-targeted-PEGylated DTX: QU NCs exhibited higher caspase-3 activity. The cell viability assay results showed the enhanced cell inhibition activity of the combinatorial DTX: QU when compared to individual DTX. Further, higher cell cytotoxicity was achieved by LHRH-targeted DTX: QU NCs as compared to their free-form or non-targeted NCs. Finally, the results of in vivo tumor localization and in vivo antitumor activity studies complimented and upheld the in vitro results, demonstrating the beneficial role of PLGA-PEG-LHRH NCs encapsulating combination of DTX and QU in combating prostate cancer (PCa).</p>
10aActive targeting10aAnticancer10aControlled release10aEPR effect10aHydrophobic10aProstate1 aShitole, Ajinkya, A.1 aSharma, Neeti1 aGiram, Prabhanjan1 aKhandwekar, Anand1 aBaruah, Meghna1 aGarnaik, Baijayantimala1 aKoratkar, Santosh  uhttp://library.ncl.res.in/content/lhrh-conjugated-pegylated-poly-lactide-co-glycolide-nanocapsules-targeted-delivery03030nas a2200289   4500008004100000022001400041245012300055210006900178260000800247300001100255490000800266520207100274653001802345653002302363653001502386653002002401653001402421653002302435100002502458700001702483700002202500700001902522700002202541700002802563700001802591856013102609       2020                        eng d  a0928-493100aPoly (vinylpyrrolidone)-iodine engineered poly (epsilon-caprolactone) nanofibers as potential wound dressing materials0 aPoly vinylpyrrolidoneiodine engineered poly epsiloncaprolactone   cMAY  a1107310 v1103 a<p>Facilitating the process of wound healing and effective treatment of wounds remains a serious challenge in healthcare. Wound dressing materials play a major role in the protection of wounds and in accelerating the natural healing process. In the present study, novel core/shell (c/s) nanofibrous mats of poly(vinyl pyrrolidone)-iodine (PVPI) and polycaprolactone (PCL) were fabricated using a co-axial electrospinning process followed by their surface modification with poly-L-lysine. The developed nanofibrous mats were extensively characterized for their physicochemical properties using various analytical techniques. The core/shell structure of the PVP-I/PCL nanofibers was confirmed using TEM analysis. The PVP-I release studies showed an initial burst phase followed by a sustained release pattern of PVP-I over a period of 30 days. The developed nanofibers exhibited higher BSA and fibrinogen adsorption as compared to pristine PCL. Cytotoxicity studies using MTT assay demonstrated that the PVP-I/PCL (c/s) nanofibers were cytocompatible at optimized PVP-I concentration (3 wt%). The PCL-poly-L-lysine and PVP-I/PCL-poly-L-lysine nanofibers exhibited higher cell viability (24.2% and 21.4% higher at day 7) when compared to uncoated PCL and PVP-I/PCL nanofibers. The PVP-I/PCL nanofibers showed excellent antimicrobial activity against both Gram-positive (S. aureus) and Gram-negative (E. coli) bacteria. The inflammatory response of Mouse RAW 264.7 macrophage cells towards the nanofibers was studied using RTPCR. It revealed that the pro-inflammatory cytokines (TNF-alpha and IL-1 beta) were significantly upregulated on PCL nanofibers, while their expression was comparatively lower on poly-L-lysine coated PCL or PVP-I/PCL(c/s) nanofibers. Overall, the study highlights the ability of poly-L-lysine coated PVP-I/PCL (c/s) nanofibers as potential wound dressing materials effectively facilitating the early stage wound healing and repair process by virtue of their selective modulation of inflammation, cell adhesion and antimicrobial properties.</p>
10abiodegradable10aControlled release10aCore/shell10aelectrospinning10ascaffolds10atissue engineering1 aShitole, Ajinkya, A.1 aRaut, Piyush1 aGiram, Prabhanjan1 aRade, Priyanka1 aKhandwekar, Anand1 aGarnaik, Baijayantimala1 aSharma, Neeti  uhttp://library.ncl.res.in/content/poly-vinylpyrrolidone-iodine-engineered-poly-epsilon-caprolactone-nanofibers-potential-wound